Mapi Pharma Ltd. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications1liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
GA DepotA multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks	SEP	Phase 3	À vérifier	United States, Belarus, Bosnia and Herzegovina, Bulgaria, Estonia, Georgia, Israel, Moldova, …	À vérifier
GA DepotA multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks	SEP	Phase 3	À vérifier	United States, Belarus, Bosnia and Herzegovina, Bulgaria, Estonia, Georgia, Israel, Moldova, Russia, Ukraine	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
GA Depot	SEP	Phase 3	NCT04121221	A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS	COMPLETED

Publications

1

Molécule	Indication / population	Titre	Journal	Date
GA Depot		GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.	Multiple sclerosis (Houndmills, Basingstoke, England)